Jeff Yass’s Ovid Therapeutics OVID Stock Holding History

Jeff Yass’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	112,900 +48,700	+76%	+$126K	﹤0.01%	11019
2026 Q1	$143K	Buy	64,200 +52,200	+435%	+$93.3K	﹤0.01%	12064
2025 Q4	$19.6K	Sell	12,000 -46,100	-79%	-$71K	﹤0.01%	11967
2025 Q3	$75.5K	Buy	+58,100	New	+$50.4K	﹤0.01%	11708
2022 Q3	–	Sell	-11,300	Closed	-$24K	–	13874
2022 Q2	$24K	Sell	11,300 -14,000	-55%	-$33.8K	﹤0.01%	12314
2022 Q1	$79K	Sell	25,300 -92,900	-79%	-$292K	﹤0.01%	12063
2021 Q4	$379K	Sell	118,200 -79,900	-40%	-$274K	﹤0.01%	9920
2021 Q3	$666K	Sell	198,100 -6,900	-3%	-$25.2K	﹤0.01%	8646
2021 Q2	$802K	Buy	205,000 +22,300	+12%	+$88K	﹤0.01%	8367
2021 Q1	$734K	Buy	182,700 +172,700	+1,727%	+$574K	﹤0.01%	8536
2020 Q4	$23K	Sell	10,000 -36,100	-78%	-$168K	﹤0.01%	10870
2020 Q3	$265K	Sell	46,100 -23,400	-34%	-$157K	﹤0.01%	8960
2020 Q2	$512K	Buy	+69,500	New	+$325K	﹤0.01%	7308

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jeff Yass's OVID Position: Q2 2026 in Review

Jeff Yass reduced its Ovid Therapeutics (OVID) stake by 96% in Q2 2026, selling an estimated $4.84M and leaving 70,600 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #12009.

Jeff Yass first reported a position in OVID in Q4 2019 and has held it in 21 quarters since. The position peaked at $4.32M in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Jeff Yass held 70,600 shares of Ovid Therapeutics worth $190K as of Q2 2026.
Jeff Yass sold 1,876,994 Ovid Therapeutics shares in Q2 2026, an estimated $4.84M.
Ovid Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12009 holding.
Jeff Yass first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 21 quarters since.
Jeff Yass's Ovid Therapeutics position peaked at $4.32M in Q1 2026.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.